COVID-19 and AMR – what do we know so far?
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new coronavirus that was only recently discovered in 2019. The virus causes the COVID-19 pandemic which currently requires the full focus, commitment and support from all governments, international institutions and organizations, the healthcare workforce, the private sector, civil society and the general public.
Some attention has started to be given to the role of secondary infections as well as antibiotic resistance in patients with COVID-19. Currently, however, too little information is available to draw any full conclusions on the potential impact antibiotic resistance might have on COVID-19 outcomes.
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
 |
BD |
AMR NEWS
Your Biweekly Source for Global AMR Insights!
Stay informed with the essential newsletter that brings together all the latest One Health news on antimicrobial resistance. Delivered straight to your inbox every two weeks, AMR NEWS provides a curated selection of international insights, key publications, and the latest updates in the fight against AMR.
Don’t miss out on staying ahead in the global AMR movement—subscribe now!